Full video transcriptClick to expand
Auto-generated transcript of @beecomingkellee's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Whoa, hey, thoughts.
- 0:04Nobody told me, switching from manjarotones,
- 0:07I think that the needle is just exposed.
- 0:11I have to push into my skin.
- 0:16Can we get my manjarot back?
- 0:18Can we have that?
- 0:19Yeah, I don't know if I can do this.
- 0:20I'm gonna try that.
- 0:21Okay, I'm not afraid of needles.
- 0:23Like I get shot to get blood drawn.
- 0:24I do fine with all of it.
- 0:26However, I don't do any of that to myself.
- 0:29That's my problem.
- 0:30Hold up, be back.
- 0:31Okay guys, so before I do this,
- 0:32yes, I ate protein.
- 0:34It's still at night, so I'm keeping that the same.
- 0:36As I deal with my manjaro,
- 0:37and I can't say when I'm in my own jailer,
- 0:39with braces, so that's how I say it.
- 0:41I can say it was in big though.
- 0:43It's good, okay.
- 0:44So anyway, kept protein the same.
- 0:47Only thing that's changing is the day.
- 0:49No longer am I doing injections on Wednesdays,
- 0:51I'm now a Thursday type girl.
- 0:54You know the best of a song.
- 0:57But I'm about to give myself this injection.
- 0:59I am scared, but let me get to the right dose
- 1:02and everything before I do.
- 1:04Okay guys, I don't know why I'm doing it.
- 1:07Okay, I'm really scared.
- 1:13I don't stab myself.
- 1:14Okay, guys, the needle does not hurt.
- 1:23Okay, here goes the medicine.
- 1:28Hold it down, it went to zero,
- 1:30which is a whole new thing, counting to six.
- 1:37And take the needle out.
- 1:43Y'all, wow y'all, like hyped me up like that.
- 1:47Like it's nothing.
- 1:51Bye, see you next week.
Switching from Mounjaro to Ozempic: what the data says
Quick answer
The creator is transitioning from tirzepatide (Mounjaro) to semaglutide (Ozempic), two GLP-1 class medications with different receptor binding profiles and delivery device mechanics. She demonstrates the Ozempic injection process in real time, including the six-second hold technique, while noting her discomfort with the manual press mechanism compared to the Mounjaro auto-injector. Her self-reported behavior of maintaining protein intake during the switch reflects a practice supported by research on preserving lean mass during GLP-1-facilitated caloric restriction.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Switching from Mounjaro to Ozempic: what the data says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Switching from Mounjaro to Ozempic: what the data says" from KellzBeeBlessed🍯. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is transitioning from tirzepatide (Mounjaro) to semaglutide (Ozempic), two GLP-1 class medications with different receptor binding profiles and delivery device mechanics.
The reason this review is not generic is the source wording and the canonical claim label "glp1 startingozempic ozempic formermounjarobaddie mounjarobaddie." In this clip, the useful excerpt is: "Whoa, hey, thoughts." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator is transitioning from tirzepatide (Mounjaro) to semaglutide (Ozempic), two GLP-1 class medications with different receptor binding profiles and delivery device mechanics.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is transitioning from tirzepatide (Mounjaro) to semaglutide (Ozempic), two GLP-1 class medications with different receptor binding profiles and delivery device mechanics. She demonstrates the Ozempic injection process in real time, including the six-second hold technique, while noting her discomfort with the manual press mechanism compared to the Mounjaro auto-injector. Her self-reported behavior of maintaining protein intake during the switch reflects a practice supported by research on preserving lean mass during GLP-1-facilitated caloric restriction.
- Mounjaro and Ozempic use different pen mechanisms: Mounjaro's KwikPen is an auto-injector; Ozempic requires pressing the dose button manually at the skin surface, which is a real ergonomic difference, not user error.
- Self-injection anxiety affects an estimated 16 to 20 percent of adults in GLP-1 and insulin-using populations and is a documented contributor to non-adherence (Polonsky and Jankovic, 2022, Diabetes Technology and Therapeutics).
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Mounjaro and Ozempic use different pen mechanisms: Mounjaro's KwikPen is an auto-injector; Ozempic requires pressing the dose button manually at the skin surface, which is a real ergonomic difference, not user error.
- Self-injection anxiety affects an estimated 16 to 20 percent of adults in GLP-1 and insulin-using populations and is a documented contributor to non-adherence (Polonsky and Jankovic, 2022, Diabetes Technology and Therapeutics).
- STEP 1 (Wilding et al., 2021, NEJM) showed semaglutide produced roughly 14.9 percent mean weight reduction; SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide up to 22.5 percent, meaning these are not equivalent medications and switching them is not a neutral swap.
- The six-second hold technique after the Ozempic dose counter reaches zero is correct per official prescribing guidance and helps ensure full subcutaneous delivery.
- Maintaining protein intake during GLP-1 therapy is evidence-backed: higher protein diets during caloric restriction help preserve lean muscle mass (Wycherley et al., 2012, American Journal of Clinical Nutrition).
- Any switch between GLP-1 medications should be managed by a licensed provider; dosing transitions are not one-to-one and require clinical judgment about starting dose and titration schedule.
- Improper injection technique, including removing the pen too early, can reduce subcutaneous drug absorption and affect treatment outcomes (Kreugel et al., 2019, Diabetes Technology and Therapeutics).
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @beecomingkellee actually say?
She's switching from Mounjaro (tirzepatide) to Ozempic (semaglutide) and immediately noticed the injection experience feels different. Her main observation: the Ozempic pen requires her to manually push the needle into her skin, whereas Mounjaro's auto-injector did that step for her. She said, "I have to push into my skin," and described being genuinely scared despite not being needle-phobic in clinical settings. She also mentioned keeping her protein intake the same and shifting her injection day from Wednesday to Thursday. The video is essentially a real-time injection anxiety moment, not a medical tutorial.
To her credit, she's transparent about what's changing and what isn't. She's not making dramatic health claims. She's documenting a routine switch between two GLP-1 medications, and her discomfort with self-injection is a real and relatable barrier that doesn't get nearly enough attention in clinical conversations about these drugs.
Does the science back this up?
Yes, the pen mechanics she noticed are real, and the anxiety around self-injection is clinically documented. The Mounjaro KwikPen uses an auto-injector mechanism. Ozempic's pre-filled pen requires the user to press the dose button at the skin surface, which feels more manual even though the needle gauge is similar.
Self-injection anxiety is not trivial. A 2022 review by Polonsky and Jankovic in Diabetes Technology and Therapeutics found that needle anxiety affects an estimated 16 to 20 percent of adults with diabetes and contributes meaningfully to medication non-adherence. The sensation of pressing a pen against skin and activating it yourself is psychologically distinct from an auto-injector click, even when the actual needle insertion depth and gauge are comparable. Her reaction is not irrational; it reflects a documented psychological phenomenon around device ergonomics and perceived control during injection.
Her mention of counting to six after the dose reaches zero also checks out. Ozempic's prescribing guidance recommends holding the pen in place for six seconds after the dose counter reaches zero to ensure full delivery, which she appears to have done correctly.
What did they get wrong (or right)?
She got the injection technique essentially right. Hold, wait for zero, count to six, remove. That matches Novo Nordisk's official Ozempic pen instructions and standard clinical guidance. Credit where it's due.
What she didn't address, and what matters if anyone watching takes this as a how-to, is that these are two meaningfully different drugs. Mounjaro is a dual GIP and GLP-1 receptor agonist. Ozempic is a GLP-1 receptor agonist only. The mechanisms are not identical, and neither are the efficacy profiles. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide achieving up to 22.5 percent mean body weight reduction. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide at approximately 14.9 percent. She doesn't claim they're equivalent, but viewers switching between them should know the pharmacology differs in ways that affect outcomes.
She also doesn't mention that switching GLP-1 medications typically requires clinical guidance on dosing transitions. That's not a criticism of her video specifically, but it's worth flagging for anyone who treats her experience as a template.
What should you actually know?
If you're switching between GLP-1 medications, the injection device ergonomics are a real and legitimate concern, not vanity. Injection technique affects drug delivery. A 2019 study by Kreugel et al. in Diabetes Technology and Therapeutics found that improper injection technique, including failure to hold the pen long enough, can reduce subcutaneous absorption. Practicing with the new pen before your first live dose is reasonable.
More importantly, switching from tirzepatide to semaglutide is not a neutral swap. These drugs bind to different receptors in different combinations. Your provider should guide the transition, including whether your dose on the new medication corresponds appropriately to where you were on the old one. Nobody should be figuring that out from a TikTok, including from this one.
Protein intake, which she mentioned keeping consistent, is a reasonable instinct. Research supports higher protein consumption during GLP-1 therapy to help preserve lean muscle mass during caloric restriction (Wycherley et al., 2012, American Journal of Clinical Nutrition). That part of her approach has real backing.
- The auto-injector versus manual press distinction between Mounjaro and Ozempic pens is real and affects user experience
- Injection anxiety is clinically documented and contributes to non-adherence
- Tirzepatide and semaglutide are pharmacologically distinct drugs with different receptor profiles
- Holding the Ozempic pen for six seconds post-dose is correct technique per prescribing guidance
- Any medication switch should be supervised by a licensed provider, not modeled on social media content
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
KellzBeeBlessed🍯 · TikTok creator
55.9K views on this video
#startingozempic #ozempic #formermounjarobaddie #mounjarobaddie #ozempicbeforeandafter #fyp #kellz2blessed
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about mounjaro?
Mounjaro and Ozempic use different pen mechanisms: Mounjaro's KwikPen is an auto-injector; Ozempic requires pressing the dose button manually at the skin surface, which is a real ergonomic difference, not user error.
What does the video say about self-injection anxiety affects an estimated 16 to 20 percent of?
Self-injection anxiety affects an estimated 16 to 20 percent of adults in GLP-1 and insulin-using populations and is a documented contributor to non-adherence (Polonsky and Jankovic, 2022, Diabetes Technology and Therapeutics).
What does the video say about step 1 (wilding et al., 2021, nejm) showed semaglutide produced?
STEP 1 (Wilding et al., 2021, NEJM) showed semaglutide produced roughly 14.9 percent mean weight reduction; SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide up to 22.5 percent, meaning these are not equivalent medications and switching them is not a neutral swap.
What does the video say about the six-second hold technique after the ozempic dose counter reaches?
The six-second hold technique after the Ozempic dose counter reaches zero is correct per official prescribing guidance and helps ensure full subcutaneous delivery.
What does the video say about maintaining protein intake during glp-1 therapy?
Maintaining protein intake during GLP-1 therapy is evidence-backed: higher protein diets during caloric restriction help preserve lean muscle mass (Wycherley et al., 2012, American Journal of Clinical Nutrition).
What does the video say about any switch between glp-1 medications should be managed by a?
Any switch between GLP-1 medications should be managed by a licensed provider; dosing transitions are not one-to-one and require clinical judgment about starting dose and titration schedule.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by KellzBeeBlessed🍯, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.